Search hospitals > Texas > Dallas
Baylor University Medical Center
Claim this profileDallas, Texas 75246
Global Leader in Leukemia
Global Leader in Lymphoma
Conducts research for Myeloid Leukemia
Conducts research for Heart Failure
Conducts research for Cancer
357 reported clinical trials
16 medical researchers
Summary
Baylor University Medical Center is a medical facility located in Dallas, Texas. This center is recognized for care of Leukemia, Lymphoma, Myeloid Leukemia, Heart Failure, Cancer and other specialties. Baylor University Medical Center is involved with conducting 357 clinical trials across 534 conditions. There are 16 research doctors associated with this hospital, such as Joyce O'Shaughnessy, MD, Andrew S Paulson, MD, Susan Mathai, MD, and Chetan Naik, MD.Area of expertise
1Leukemia
Global LeaderCD19 positive
Philadelphia chromosome positive
Philadelphia chromosome negative
2Lymphoma
Global LeaderCD19 positive
TP53 positive
CD20 positive
Top PIs
Joyce O'Shaughnessy, MDTexas Oncology-Baylor Charles A. Sammons Cancer Center7 years of reported clinical research
Expert in Breast Cancer
Studies Tumors
19 reported clinical trials
36 drugs studied
Andrew S Paulson, MDTexas Oncology - Baylor Charles A. Sammons Cancer Center1 year of reported clinical research
Studies Colorectal Cancer
Studies Tumors
5 reported clinical trials
9 drugs studied
Susan Mathai, MDBaylor Scott & White Research Institute1 year of reported clinical research
Studies Pulmonary Fibrosis
Studies Fibrosis
5 reported clinical trials
7 drugs studied
Chetan Naik, MDBaylor University Medical Center5 years of reported clinical research
Studies Bronchiolitis
Studies Bronchiolitis Obliterans
4 reported clinical trials
4 drugs studied
Clinical Trials running at Baylor University Medical Center
Multiple Myeloma
Non-Hodgkin's Lymphoma
Lymphoma
Crohn's Disease
Plasma Cell Neoplasms
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Fibrosis
Heart Failure
Surgical Site Infection
Elranatamab Combinations
for Multiple Myeloma
The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody elranatamab, alone and/or in combination with the anti-CD38 monoclonal antibody, daratumumab, can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone. People with multiple myeloma who have received previous treatment including lenalidomide and a proteasome inhibitor will be enrolled in the study. Part 1 of the study will assess the safety and activity of different doses of elranatamab in combination with daratumumab. People participating in Part 2 of the study will be randomly assigned to receive either elranatamab alone, elranatamab plus daratumumab, or daratumumab, pomalidomide, and dexamethasone. Part 2 will compare the safety and activity of (1) elranatamab alone compared to daratumumab, pomalidomide, and dexamethasone, and (2) elranatamab plus daratumumab compared to daratumumab, pomalidomide, and dexamethasone. Participants in all parts of the study will receive study treatment until their disease progresses, they experience unacceptable side effects, or they choose to no longer participate in the study.
Recruiting2 awards Phase 36 criteria
Daratumumab
for Multiple Myeloma
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have reached clinical cutoff for final analysis. Certain long-term safety data will continue to be collected from study participants.
Recruiting2 awards Phase 36 criteria
Elranatamab vs Lenalidomide
for Multiple Myeloma
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years
Recruiting2 awards Phase 38 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Baylor University Medical Center?
Baylor University Medical Center is a medical facility located in Dallas, Texas. This center is recognized for care of Leukemia, Lymphoma, Myeloid Leukemia, Heart Failure, Cancer and other specialties. Baylor University Medical Center is involved with conducting 357 clinical trials across 534 conditions. There are 16 research doctors associated with this hospital, such as Joyce O'Shaughnessy, MD, Andrew S Paulson, MD, Susan Mathai, MD, and Chetan Naik, MD.
Where is Baylor University Medical Center located?
**Baylor University Medical Center, Dallas, Texas**
- **Address:** 3500 Gaston Ave, Dallas, TX 75246
- **Location:** Near the intersection of Gaston Avenue and Junius Street.
- **Parking:** Multiple parking garages and valet services available.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Baylor University Medical Center, contact Eligibility and Enrollment Services at 972.892.3026. For insurance inquiries, visit the Insurance office next to the registration desk in the Medical Clinic, 2nd floor of the McLane Student Life Center, or contact them at 254-710-7425. Address correspondence to Baylor University Health Services Insurance Office, One Bear Place #97060, Waco, TX 76798.
What insurance does Baylor University Medical Center accept?
The Baylor University Medical Center accepts a wide range of insurance plans, including Traditional Medicaid, Traditional Medicare, and any Medicare Supplement/Medigap plan not tied to a network. They are also contracted providers for various insurance companies and networks, including Aetna, Blue Cross Blue Shield, Cigna HealthCare, and Humana. It's important to confirm coverage with your insurance provider before scheduling any visits or procedures.
What awards or recognition has Baylor University Medical Center received?
Baylor University Medical Center in Dallas, Texas, is renowned for its exceptional maternity services, earning a Level IV Maternity designation and ranking among the nation's top 50 gynecology programs by U.S. News and World Report. The hospital offers advanced wound care, including hyperbaric oxygen therapy and specialized treatments for hard-to-heal wounds. In 2022, it received over $15 million in grants, supported by the Baylor Scott & White Dallas Foundation and Dallas Safety Net Support Corporation, enhancing patient care, education, medical research, and community service.